RBC Capital Maintains Outperform on Axsome Therapeutics, Raises Price Target to $130
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has maintained its Outperform rating on Axsome Therapeutics (NASDAQ:AXSM) and raised the price target from $127 to $130.
June 05, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained its Outperform rating on Axsome Therapeutics and raised the price target from $127 to $130.
The raised price target and maintained Outperform rating from RBC Capital are positive signals for investors, likely leading to a short-term increase in AXSM's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100